Analysts expect Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) to report sales of $1.06 billion for the current quarter, Zacks Investment Research reports. Eight analysts have issued estimates for Alexion Pharmaceuticals’ earnings, with estimates ranging from $1.04 billion to $1.13 billion. Alexion Pharmaceuticals reported sales of $909.70 million in the same quarter last year, which indicates a positive year over year growth rate of 16.5%. The company is expected to report its next earnings report on Thursday, February 14th.
According to Zacks, analysts expect that Alexion Pharmaceuticals will report full-year sales of $4.07 billion for the current year, with estimates ranging from $4.04 billion to $4.13 billion. For the next financial year, analysts expect that the firm will report sales of $4.76 billion, with estimates ranging from $4.50 billion to $4.92 billion. Zacks’ sales averages are a mean average based on a survey of sell-side research analysts that follow Alexion Pharmaceuticals.
Alexion Pharmaceuticals (NASDAQ:ALXN) last announced its earnings results on Wednesday, October 24th. The biopharmaceutical company reported $2.02 EPS for the quarter, topping the consensus estimate of $1.74 by $0.28. The business had revenue of $1.03 billion for the quarter, compared to the consensus estimate of $1.02 billion. Alexion Pharmaceuticals had a return on equity of 16.60% and a net margin of 3.90%. Alexion Pharmaceuticals’s revenue was up 19.5% compared to the same quarter last year. During the same period in the previous year, the business earned $1.44 EPS.
Several brokerages have recently commented on ALXN. Oppenheimer set a $165.00 target price on Alexion Pharmaceuticals and gave the stock a “buy” rating in a report on Monday, November 26th. Credit Suisse Group set a $156.00 price objective on shares of Alexion Pharmaceuticals and gave the stock a “buy” rating in a research report on Tuesday, November 13th. ValuEngine upgraded shares of Alexion Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday, November 8th. Zacks Investment Research upgraded shares of Alexion Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $134.00 price objective for the company in a research report on Tuesday, October 30th. Finally, Citigroup dropped their price objective on shares of Alexion Pharmaceuticals from $195.00 to $190.00 and set a “buy” rating for the company in a research report on Thursday, October 25th. Four investment analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus target price of $161.50.
Shares of ALXN opened at $123.15 on Monday. The company has a market capitalization of $27.47 billion, a PE ratio of 23.87, a price-to-earnings-growth ratio of 1.06 and a beta of 0.99. The company has a debt-to-equity ratio of 0.32, a quick ratio of 2.74 and a current ratio of 3.16. Alexion Pharmaceuticals has a one year low of $102.10 and a one year high of $140.77.
In related news, EVP Indrani Lall Franchini sold 2,605 shares of the business’s stock in a transaction that occurred on Wednesday, November 28th. The shares were sold at an average price of $118.13, for a total value of $307,728.65. Following the completion of the transaction, the executive vice president now owns 29,304 shares in the company, valued at approximately $3,461,681.52. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 4.35% of the company’s stock.
Several institutional investors have recently modified their holdings of the business. Clearbridge Investments LLC raised its position in shares of Alexion Pharmaceuticals by 15.4% during the 3rd quarter. Clearbridge Investments LLC now owns 5,178,157 shares of the biopharmaceutical company’s stock valued at $719,816,000 after acquiring an additional 691,390 shares during the last quarter. Vanguard Group Inc. raised its position in shares of Alexion Pharmaceuticals by 1.2% during the 3rd quarter. Vanguard Group Inc. now owns 15,811,291 shares of the biopharmaceutical company’s stock valued at $2,197,928,000 after acquiring an additional 192,857 shares during the last quarter. Morgan Stanley raised its position in shares of Alexion Pharmaceuticals by 2.1% during the 3rd quarter. Morgan Stanley now owns 781,891 shares of the biopharmaceutical company’s stock valued at $108,691,000 after acquiring an additional 16,017 shares during the last quarter. Legal & General Group Plc raised its position in shares of Alexion Pharmaceuticals by 1.4% during the 3rd quarter. Legal & General Group Plc now owns 960,726 shares of the biopharmaceutical company’s stock valued at $133,550,000 after acquiring an additional 13,631 shares during the last quarter. Finally, Neuberger Berman Group LLC raised its position in shares of Alexion Pharmaceuticals by 11.7% during the 3rd quarter. Neuberger Berman Group LLC now owns 585,888 shares of the biopharmaceutical company’s stock valued at $81,445,000 after acquiring an additional 61,309 shares during the last quarter. Institutional investors own 96.62% of the company’s stock.
About Alexion Pharmaceuticals
Alexion Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers Soliris (eculizumab), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; atypical hemolytic uremic syndrome (aHUS), a genetic disease; and generalized myasthenia gravis, a debilitating, complement-mediated neuromuscular disease.
Featured Article: What is a capital gain?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.